7.35
-0.02 (-0.27%)
| Penutupan Terdahulu | 7.37 |
| Buka | 7.41 |
| Jumlah Dagangan | 100,395 |
| Purata Dagangan (3B) | 1,297,935 |
| Modal Pasaran | 701,985,024 |
| Harga / Jualan (P/S) | 606.20 |
| Harga / Buku (P/B) | 7.12 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Aug 2026 |
| Margin Operasi (TTM) | -1,621.58% |
| EPS Cair (TTM) | -1.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.72% |
| Nisbah Semasa (MRQ) | 9.08 |
| Aliran Tunai Operasi (OCF TTM) | -56.39 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.34 M |
| Pulangan Atas Aset (ROA TTM) | -41.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -71.90% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Shattuck Labs, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.67 |
|
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 14.36% |
| % Dimiliki oleh Institusi | 64.06% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |